The relationship between treatment outcome and cutaneous toxicity induced by anticancer
therapy has gained attention in the past decade. In this article, we have provided an …

Over the past 2 decades, rapid advancement in systemic anticancer therapeutics has led to
astounding improvement in survival rates of patients with cancer. However, this celebrated …

The increased approval of anticancer agents has led to unprecedented results, with
improved quality of life and longer survival times, resulting in millions of individuals living …

Conventional anticancer agents target rapidly dividing cells, which explains the common
adverse effects (AEs) seen in organ systems with a dominant population of proliferative …

Antineoplastic agents that use the immune system have revolutionized cancer treatment.
Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that …

In recent years, targeted agents have rapidly evolved as effective tools in the clinical
management of a broad range of malignant diseases. These agents disrupt molecular …

Background Dermatologic toxicities (DT) to targeted cancer therapy may present as
inflammatory dermatoses, keratoses, and as benign and malignant squamous proliferations …

Over the past decade, numerous targeted therapeutic agents have become available for
clinical use in the oncologic setting with the hopes of realizing personalized cancer …

Cancer therapies have led to remarkable results due to improved toxicity profiles and effects
on survival. While these medical, surgical, and radiation protocols are chiefly responsible for …

The arrival of targeted therapeutics into the oncology clinic, while enthusiastically
anticipated, introduced the oncologist to dermatologic events that can pose challenging …